News Detail
New Delhi, 29 June 2024: Popular peptide drugs for diabetes and obesity — Glucagon-like peptide receptor agonist (GLP-1RA) — will be manufactured in India under the production linked incentive (PLI) scheme from 2026 when the patents expire, a ......
View Details
View Details
Source : Business Standard
diabetes medicine
sun pharmaceutical industries ltd
cipla ltd
India Ozempic
Obesity
Obesity medicine
Obesity drugs
Obesity medicines
diabetes
diabetes drugs
Related News
- 529 Drug Samples declared NSQ and 55 Spurious in last three calendar years in Rajasthan: Govt in LS (31-03-2025)
- WB writes to Bihar and UP governments about spurious drugs makers (31-03-2025)
- Dabur to Drop ‘Anti-Inflammatory’, ‘Anti-Bacterial’, ‘Analgesic’ Claims from Toothpaste Labels by June 2025 (31-03-2025)
- Kangra: One person arrested from Delhi in drug case (30-03-2025)
- RMSCL to address drugs shortage using automated demand system (30-03-2025)
- Raids on chemist shops across Gujarat, 50 lakh Codeine Cough Syrup bottles seized (30-03-2025)
- Pluvicto can now be used before chemotherapy to treat a kind of metastatic prostate cancer (30-03-2025)
- HC asks Centre, Delhi govt to disclose regulatory mechanism for blood banks in city (30-03-2025)
- Meghalaya’s Citrus offers hope against antibiotic resistance (30-03-2025)
- Counterfeit anti-rabies vaccine circulating in major Indian cities (30-03-2025)